Clinical Trial Update: AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AKT inhibitor MK-2206 in relapsed or refractory adult acute leukemias completed; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Del
• Acute Myeloid Leukemia with Inv
• Erythroleukemia
• Megakaryoblastic Leukemia
• Minimally Differentiated Myeloid Leukemia
• Monoblastic Leukemia
• Monocytic Leukemia
• Myeloblastic Leukemia Without Maturation
• Myeloblastic Leukemia with Maturation
• Myelomonocytic Leukemia
• Pure Erythroid Leukemia

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Status: COMPLETED | Results posted: 2015-01-07